Invitation to the EBAC-accredited Satellite Symposium "Novel Therapies in Managing Patients with Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure".
Cardiovascular-Kidney-Metabolic syndrome (CKM) is a progressive disease that affects multiple organs. It exists as a spectrum ranging from risk to clinical disease.
In this program, three experts will discuss CKM syndrome and focus on heart failure as CKM conditions frequently coexist in individuals with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). They'll discuss the disease burden in patients, the latest outcomes of novel therapies for these conditions, and how these findings can be applied in real-world scenarios through a case presentation.
For more information, please visit the ESC Preventive Cardiology website.
Educational objectives
The educational objectives of the symposium are to:
- Implement structured approaches for coordinated care between cardiologists, primary care physicians, and other members of the interprofessional care team to improve the quality of life in patients with HF and CKM syndrome.
- Evaluate the efficacy and safety of emerging therapies in patients with HF with mildly reduced or preserved ejection fraction, considering their impact on morbidity, mortality, and quality of life.
- Develop comprehensive evidence-based management plans for managing patients with HF and CKM syndrome.
Agenda
12:45 – 12:50 Introduction - Riccardo M. Inciardi, MD, PhD – Brescia, Italy
12:50 – 13:05 Understanding the burden of CKM syndrome and HFmrEF/HFpEF - Cristina Gavina, MD, PhD - Porto, Portugal
13:05 – 13:20 Transforming CKM syndrome and HFmrEF/HFpEF management: long-term estimated benefits of integrated strategies - Riccardo M. Inciardi, MD, PhD – Brescia, Italy
13:20 – 13:35 Implementing evidence into preventive practice: A case-based approach -Giuseppe Galati, MD – Milan, Italy
13:35 – 13:45 Panel discussion: therapeutic opportunities for optimizing prevention & long-term outcomes and Q&A - All faculty
CME Accreditation
This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) with 60 minutes effective education time. Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).
Funding
This program is supported by an unrestricted educational grant from Bayer AG.
